ArticleKidney medicine2022
Posttransplant Diabetes Mellitus and Immunosuppression Selection in Older and Obese Kidney Recipients.
Article in Kidney medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Are We Winning at Twinning? Persistent CNI Use in Identical Kidney Transplants.Clinical transplantation · 2026Article
- Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report.Clinical transplantation · 2026Article
- Abdominal Waist Circumference and Subcutaneous Adipose Tissue Thickness Predicts Development of Post-Transplant Diabetes Mellitus.Research square · 2026Article
- Kidney Transplantation in Advanced Octogenarians: The World's Oldest Kidney Transplant Recipient.Canadian journal of kidney health and disease · 2026Article
- New-Onset Diabetes After Transplantation in Renal Recipients: A Pilot Comparative Study of Immediate vs. Extended-Release Tacrolimus Formulation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Twenty-Year Kidney Transplant Outcomes With Prednisone-Free Maintenance Immunosuppression: A Matched Control Analysis.Clinical transplantation · 2025Article
- Kidney Transplantation in Older Recipients: One-Year Outcomes and Complications from a Single-Center Experience.Journal of clinical medicine · 2025Article
- Trends and predictors of diabetes mellitus after living kidney transplantation: A retrospective study.World journal of diabetes · 2025Article
- Association of COVID-19 With Risk of Posttransplant Diabetes Mellitus.Transplantation · 2025Article
- Early steroid withdrawal and kidney transplant outcomes in first-transplant and retransplant recipients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences.Diagnostics (Basel, Switzerland) · 2025Review
- The incidence and risk factors of post-transplant diabetes mellitus in living donor kidney transplantation patients: a retrospective study.BMC nephrology · 2024Article
- New-Onset Diabetes Mellitus after Kidney Transplantation.Journal of clinical medicine · 2024Review
- Distinct phenotypes of kidney transplant recipients aged 80 years or older in the USA by machine learning consensus clustering.BMJ surgery, interventions, & health technologies · 2023Article
- New-Onset Diabetes Mellitus in Post-renal Transplant Patients on Tacrolimus and Mycophenolate: A Systematic Review.Cureus · 2022Review
- Kidney Transplantation, Immunosuppression and the Risk of Fracture: Clinical and Economic Implications.Kidney medicine · 2022Article
- Progress and Recent Advances in Solid Organ Transplantation.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
Abstract
RATIONALE &
objectivePosttransplant diabetes mellitus (DM) after kidney transplantation increases morbidity and mortality, particularly in older and obese recipients. We aimed to examine the impact of immunosuppression selection on the risk of posttransplant DM among both older and obese kidney transplant recipients. STUDY
designRetrospective database study. SETTING &
participantsKidney-only transplant recipients aged ≥18 years from 2005 to 2016 in the United States from US Renal Data System records, which integrate Organ Procurement and Transplantation Network/United Network for Organ Sharing records with Medicare billing claims. EXPOSURES: Various immunosuppression regimens in the first 3 months after transplant. OUTCOMES: Development of DM >3 months-to-1 year posttransplant. ANALYTICAL APPROACH: We used multivariable Cox regression to compare the incidence of posttransplant DM by immunosuppression regimen with the reference regimen of thymoglobulin (TMG) or alemtuzumab (ALEM) with tacrolimus + mycophenolic acid + prednisone using inverse propensity weighting.
results12.7% of kidney transplant recipients developed posttransplant DM with higher incidences in older (≥55 years vs <55 years: 16.7% vs 10.1%) and obese (body mass index [BMI] ≥ 30 kg/m LIMITATIONS: Retrospective study and lacked data on immunosuppression levels.
conclusionsThe beneficial impact of steroid avoidance using tacrolimus on posttransplant DM appears to differ by patient age and induction regimen.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.